View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 6, 2021

Takeda to stop Phase II trials of TAK-994 due to safety signal 

Takeda will assess the risk-benefit profile of the oral therapy, which obtained breakthrough status from US FDA in July.

Takeda Pharmaceutical has decided to halt the dosing of subjects in the Phase II clinical trials of its oral drug, TAK-994, after a safety signal emerged.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

An experimental orexin agonist, TAK-994 can potentially act on orexin 2 receptors.

Takeda decided to halt the Phase II trials immediately as a precautionary measure.

This permits for timely benefit/risk profile analysis of TAK-994 and to decide on the further steps of the programme.

Takeda Pharmaceutical Neuroscience therapeutic area unit head Sarah Sheikh said: “Ensuring the safety of patients participating in clinical studies is of the utmost importance as we strive to develop transformative medicines.

“Takeda is committed to bringing innovative, safe and effective treatments to patients with narcolepsy. We are working to quickly assess the totality of available data to inform the further development of TAK-994.”

In July this year, TAK-994 obtained breakthrough therapy status from the US Food and Drug Administration (FDA).

TAK-994 was being analysed to treat excessive daytime sleepiness (EDS) in people with narcolepsy type 1 (NT1).

A chronic neurological disorder, NT1 modifies the sleep-wake cycle.

The FDA granted breakthrough status to TAK-994 partly based on clinical findings from early phase and initial studies.

These data showed the drug’s potential ability to significantly boost objective, as well as subjective, daytime wakefulness measurements in people with NT1.

Takeda noted that the company is progressing its multi-asset orexin franchise which comprises TAK-861, the oral orexin agonist.

TAK-861 is currently being evaluated in the Phase I trial.

Last month, Takeda reported that its investigational drug, pevonedistat, in combination with azacitidine, failed to meet the primary endpoint of the Phase III PANTHER trial in rare leukaemia patients.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU